A new treatment for patients with cervical cancer could help them stay alive longer, even if they eventually die.

A study published in the journal Nature on Tuesday suggests that the treatment, called an integrin peptide, could be an effective treatment for the disease.

The researchers, led by Dr. Hui Huang at the University of California, San Diego, said the study is the first to demonstrate that integrin-containing peptides have clinical benefits in the treatment of cervical cancer.

Huang, who also is a professor of radiology at the UCSD School of Medicine, said a recent study in the Journal of Clinical Oncology demonstrated that a similar peptide treatment, used in other cancers, can extend survival for about 40 percent of patients.

Huang said that is the same as the treatment found in the study.

He said the new study shows that the peptides may also help slow the progression of cervical cancers and prolong survival.

This could have major implications for treatment and progression in the disease, he said.

One way to extend survival is to reduce inflammation, which can lead to cancerous growths.

Other studies have shown that integrins also can extend life.

To investigate the effects of the peptide treatments on the progression and survival of the disease in mice, Huang and his colleagues used a genetically engineered strain of mice.

They then tested the peptids in mice to see whether they reduced the tumorigenesis of the tumor.

The results showed that when they injected the peptidin into mice, the tumor was less aggressive.

These results suggest that the treatments may also reduce inflammation and prolong the survival of patients with cancer, the researchers said.